Who are Premarin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Premarin, Premarin, Estrace 0.01% Vaginal Cream, Estradiol patch, Postmenopausal, topical vaginal estrogen cream, Estrogen vaginal cream.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/premphase-14-14.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Premarin — Competitive Intelligence Brief

Premarin (Estrogens, Conjugated) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Estrogen replacement therapy.

marketed Estrogen replacement therapy Estrogen receptors (nuclear receptors) Live · refreshed every 30 min

Target snapshot

Premarin (Estrogens, Conjugated) — Pfizer. Conjugated estrogens bind to nuclear estrogen receptors in estrogen-responsive tissues, modulating gonadotropin secretion and reducing elevated LH and FSH levels in postmenopausal women.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Premarin TARGET	Estrogens, Conjugated	Pfizer	marketed	Estrogen replacement therapy	Estrogen receptors (nuclear receptors)	1942-01-01
Premarin	Estrogens, Conjugated	Pfizer	marketed	Estrogen replacement therapy	Estrogen receptors (nuclear receptors)	1942-01-01
Premarin	Estrogens, Conjugated	Pfizer	marketed	Estrogen replacement therapy	Estrogen receptors (nuclear receptors)	1942-01-01
Estrace 0.01% Vaginal Cream	Estrace 0.01% Vaginal Cream	University of California, Irvine	marketed	Estrogen replacement therapy	Estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ)
Estradiol patch	Estradiol patch	University of Virginia	marketed	Estrogen replacement therapy	Estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ)
Postmenopausal, topical vaginal estrogen cream	Postmenopausal, topical vaginal estrogen cream	The University of Texas Medical Branch, Galveston	marketed	Estrogen replacement therapy (topical)	Estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ)
Estrogen vaginal cream	Estrogen vaginal cream	The University of Texas Health Science Center, Houston	marketed	Estrogen replacement therapy (topical)	Estrogen receptor alpha and beta

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Estrogen replacement therapy class)

Pfizer · 3 drugs in this class
CONRAD · 1 drug in this class
Mylan Pharmaceuticals Inc · 1 drug in this class
University of California, Irvine · 1 drug in this class
University of Virginia · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Premarin — Competitive Intelligence Brief. https://druglandscape.com/ci/premphase-14-14. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab